Physician profile
Mary G Ashmead
NPI 1275769754
$140,688.88
in general payments reported to CMS, 2019-2025
25 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $663 · 2021: $3,160 · 2022: $30K · 2023: $34K · 2024: $31K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $72K · Travel and Lodging: $15K · Food and Beverage: $9,524 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,600 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,250.00 |
| Travel and Lodging | $15,302.50 |
| Food and Beverage | $9,523.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,600.00 |
| Education | $145.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $90,050.40 | 2021-2025 | |
| Medtronic, INC. | $29,391.02 | 2022-2025 | Propel, Stealthstation S8 Platform, Straightshot |
| Neurent Medical Limited | $11,446.82 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Stryker Corporation | $4,718.03 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Clarifix |
| Intersect Ent, INC. | $1,926.44 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $621.10 | 2019-2025 | Dupixent |
| Integra Lifesciences Corporation | $477.37 | 2019-2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Optinose US, INC. | $466.37 | 2020-2025 | |
| Genzyme Corporation | $285.98 | 2021-2025 | |
| Acclarent, INC | $225.29 | 2022-2023 | Relieva Spinplus, Acclarent Aera, Acclarent Navwire |
| Olympus America INC. | $162.60 | 2023-2024 | Rhino-Laryngo Videoscope, Olympus |
| Alk-Abello, INC | $148.94 | 2019-2025 | Neffy, Ragwitek, Grastek |
| Glaxosmithkline, LLC. | $114.22 | 2023-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $111.94 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $98.49 | 2023-2025 | Ryaltris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $98.06 | 2019-2025 | Tezspire |
| Cook Medical LLC | $93.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.70 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $34.78 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $34.13 | 2021-2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Covidien Lp | $31.79 | 2020 | |
| Smith+Nephew, INC. | $31.39 | 2020 | |
| Philips North America LLC | $22.01 | 2023 | |
| Arbor Pharmaceuticals, INC. | $18.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ashmead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.